Overview

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients
Phase:
Phase 2
Details
Lead Sponsor:
Alnylam Pharmaceuticals